Evidence map›Paper›PMID 26891910›Full record

ArticleJournal of gastroenterology2016

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Ichisnosuke Hyodo

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018
    Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Takeshi YamadaDepartment of Gastroenterology, University of Tsukuba, Tsukuba, Japan. t.yamada718@md.tsukuba.ac.jp.
Yoshiyuki YamamotoDepartment of Gastroenterology, University of Tsukuba, Tsukuba, Japan.
Toshikazu MoriwakiDepartment of Gastroenterology, University of Tsukuba, Tsukuba, Japan.
Ichisnosuke HyodoDepartment of Gastroenterology, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TrastuzumabAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorHumansStomach NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorTrastuzumab

Identifiers

PMID26891910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.